Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab beta for relapsed or refractory primary membranous nephropathy
ChiCTR2600134364Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of obinutuzumab beta in idiopathic membranous glomerulonephritis (IMG), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: Complete remission rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
obinutuzumab beta
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2600134364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134364.